DGX
Quest Diagnostics Incorporated
NYSE: DGX · HEALTHCARE · DIAGNOSTICS & RESEARCH
$250.81
-0.40% today
Updated 2026-11-02
Market cap
$27.11B
P/E ratio
24.46
P/S ratio
2.29x
EPS (TTM)
$10.04
Dividend yield
1.39%
52W range
$168 – $253
Volume
1.1M
WallStSmart proprietary scores
64
out of 100
Grade: C+
Hold
Investment rating
6.0
Growth
B6.5
Quality
B6.5
Profitability
B4.0
Valuation
C5/9
Piotroski F-Score
Moderate
2.4
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →253 stocks currently score above 75
Price targets
Analyst target
$208.62
-16.82%
12-Month target
$196.69
-21.58%
Intrinsic (DCF)
$111.82
Margin of safety
-87.19%
2 Strong Buy7 Buy7 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $574.00M — positive
Risks
- 87.19% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $9.88B | $9.25B | $9.87B | $11.04B | $11.84B | $11.9B |
| Net income | $946.00M | $854.00M | $871.00M | $992.00M | $312.00M | — |
| EPS | — | — | — | — | $10.04 | $10.74 |
| Free cash flow | $1.31B | $864.00M | $909.00M | $1.36B | $574.00M | — |
| Profit margin | 9.57% | 9.23% | 8.82% | 8.99% | 9.54% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-10-26 | PFEIFFER, GARY M | S | 1,203 | $243.00 |
| 2026-10-21 | SAMAD, SAM | Buy | 90 | $235.94 |
| 2026-10-21 | PLEWMAN, PATRICK | L | 41 | $235.94 |
Peer comparison
Smart narrative
Quest Diagnostics Incorporated trades at $250.81. representing a P/E of 24.46x trailing earnings. Our Smart Value Score of 64/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 2.37, it sits in the grey zone. TTM revenue stands at $11.84B. with profit margins at 9.54%. Our DCF model estimates intrinsic value at $111.82.
Frequently asked questions
What is Quest Diagnostics Incorporated's stock price?
Quest Diagnostics Incorporated (DGX) trades at $250.81, on a P/E of 24.5x and a P/S of 2.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Quest Diagnostics Incorporated overvalued?
Quest Diagnostics Incorporated carries a Smart Value Score of 64/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $111.82 against the $250.81 price, so on cash flow terms the market is paying a premium for Quest Diagnostics Incorporated's growth. The Hold rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Quest Diagnostics Incorporated (DGX)?
The 12-month analyst consensus target is $208.62, about 16.8% below the current $250.81. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of DGX by 2030?
Our research-backed model puts the 2030 base case at $1,504.95, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Quest Diagnostics Incorporated (DGX)?
Our DCF model estimates intrinsic value at $111.82, a -87.2% margin of safety versus today's $250.81. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Quest Diagnostics Incorporated's revenue?
Quest Diagnostics Incorporated's trailing twelve-month revenue is $11.84B, and our model projects it reaching about $14.02B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Quest Diagnostics Incorporated's Altman Z-Score is 2.37, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio2.29x
ROE14.79%
Beta0.54
50D MA$238.10
200D MA$211.46
Shares out0.11B
Float0.11B
Short ratio—
Avg volume1.1M
Performance
1 week+3.40%
1 month+7.49%
3 months+7.31%
YTD+44.53%
1 year+40.24%
3 years—
5 years—